Pharmacokinetics of sulbactam/ampicillin in humans: a review
- PMID: 3025997
- DOI: 10.1093/clinids/8.supplement_5.503
Pharmacokinetics of sulbactam/ampicillin in humans: a review
Abstract
The parenteral kinetics of sulbactam, a potent synergist with ampicillin against a broad range of clinically important organisms in humans, are similar to those of ampicillin. The kinetics of ampicillin were not affected by co-administration of sulbactam, and high levels of both agents were attained: 15-min infusions of 2 g of ampicillin plus 1 g of sulbactam produced peak serum concentrations of approximately 120 micrograms of ampicillin/ml plus 60 micrograms of sulbactam/ml; intramuscular injections of 1 g of ampicillin plus 0.5 g of sulbactam produced peak concentrations of 18 micrograms of ampicillin/ml plus 13 micrograms of sulbactam/ml. The drugs had similar half-lives (approximately 1 hr), and both drugs were excreted primarily in the urine (greater than 75%). Although the kinetics of sulbactam in postpartem women and in surgical patients were similar to the kinetics in young men, the half-life of sulbactam (like that of ampicillin) was altered in the elderly, during labor, in neonates, and in patients with renal impairment. After distribution of the agents in the body, the concentrations of both drugs in blister and parenteral fluid were similar to those in serum. Furthermore, useful antibacterial concentrations of both drugs were found in pus, sputum, and middle-ear fluid. The normally low penetration of sulbactam and ampicillin into cerebrospinal fluid was increased in patients with bacterial meningitis.
Similar articles
-
The parenteral kinetics of ampicillin/sulbactam in man.Int J Clin Pharmacol Res. 1985;5(2):79-86. Int J Clin Pharmacol Res. 1985. PMID: 2991150
-
Biliary pharmacokinetics of sulbactam plus ampicillin in humans.Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S589-92. doi: 10.1093/clinids/8.supplement_5.s589. Rev Infect Dis. 1986. PMID: 3026008
-
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.Antimicrob Agents Chemother. 1982 Apr;21(4):565-7. doi: 10.1128/AAC.21.4.565. Antimicrob Agents Chemother. 1982. PMID: 6282211 Free PMC article.
-
Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.Drugs. 1987 Jun;33(6):577-609. doi: 10.2165/00003495-198733060-00003. Drugs. 1987. PMID: 3038500 Review.
-
Ampicillin/sulbactam in lower respiratory tract infections: a review.Clin Ther. 1991 Nov-Dec;13(6):714-26. Clin Ther. 1991. PMID: 1790546 Review.
Cited by
-
Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.Antimicrob Agents Chemother. 2012 Feb;56(2):838-44. doi: 10.1128/AAC.05551-11. Epub 2011 Nov 28. Antimicrob Agents Chemother. 2012. PMID: 22123698 Free PMC article.
-
Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.Antimicrob Agents Chemother. 1997 Apr;41(4):721-7. doi: 10.1128/AAC.41.4.721. Antimicrob Agents Chemother. 1997. PMID: 9087477 Free PMC article.
-
In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14. Epub 2015 May 11. Antimicrob Agents Chemother. 2015. PMID: 25963982 Free PMC article.
-
Management of meningitis due to antibiotic-resistant Acinetobacter species.Lancet Infect Dis. 2009 Apr;9(4):245-55. doi: 10.1016/S1473-3099(09)70055-6. Lancet Infect Dis. 2009. PMID: 19324297 Free PMC article. Review.
-
Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.Clin Pharmacokinet. 1988 Sep;15(3):133-64. doi: 10.2165/00003088-198815030-00001. Clin Pharmacokinet. 1988. PMID: 3052984 Review.